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Overview
Smokable herbal mixtures under the brand name ‘Spice’ are known to have been sold on the 
Internet and in various specialised shops since at least 2006 and metadata reports (Google 
Insights web searches) suggest that those products may have been available as early as 2004. 
Although advertised as an ‘exotic incense blend which releases a rich aroma’ and ‘not for human 
consumption’, when smoked, ‘Spice’ products have been reported by some users to have effects 
similar to those of cannabis.
There are a number of products marketed under the ‘Spice’ brand — these include, but are not 
limited to: Spice Silver, Spice Gold, Spice Diamond, Spice Arctic Synergy, Spice Tropical Synergy, 
Spice Egypt, etc. In addition, there are many other herbal preparations for which the claim is made 
that they have a similar make-up to ‘Spice’ — e.g. Yucatan Fire, Smoke, Sence, ChillX, Highdi’s 
Almdröhner, Earth Impact, Gorillaz, Skunk, Genie, Galaxy Gold, Space Truckin, Solar Flare, Moon 
Rocks, Blue Lotus, Aroma, Scope, etc. It should be noted that the speed of innovation in this area 
means that any list of products is likely to become quickly outdated.
Following a report from the Swedish Reitox national focal point (NFP), of a small number (around 
10) of seizures of ‘Spice’ products in 2007, the Reitox early-warning system (EWS) on new 
psychoactive substances began, from the start of 2008, formally monitoring these products. 
However, despite various media reports and users’ accounts on the Internet, little verifiable 
information on the psychoactive and other effects of ‘Spice’ was officially reported to the EMCDDA 
prior to December 2008.
Towards the end of 2008, forensic investigations were undertaken by German and Austrian 
authorities in order to identify the psychoactive ingredients of ‘Spice’. On 19 December 2008, the 
Austrian NFP formally notified to the EMCDDA the new psychoactive substance JWH-018 
(Naphthalen-1-yl-(1-pentylindol-3-yl)methanone) (1) — a synthetic cannabinoid receptor (CB) 
agonist (2) that had been identified in ‘Spice’ products in Austria by AGES PharmMed (3). The 
compound was detected in at least three products (Spice Gold, Silver and Diamond). Information 
received from the German NFP reported that JWH-018 had also been identified a few days earlier 
(on 15 December) in ‘Spice’ products in Germany by THC-Pharm (Steup, 2008) (4). JWH-018 is a 
synthetic substance first synthesized in 1995 for experimental purposes. It is a naphthoylindole, 
which belongs to the aminoalkylindole family (Wiley et al., 1998; Huffman, 2009; Chin et al., 
1999), i.e. the chemical structure differs substantially from Δ9-tetrahydrocannabinol (THC), but it 
produces similar effects in animal experiments and has been reported to be more potent than THC; 
see Uchiyama, 2009 and Auwärter et al., 2009 for analytical details. JWH-018 has also been 
reported by Poland, the United Kingdom, Slovakia, Finland and Ireland.
(1) The common chemical name for JWH-018 is 1-Pentyl-3-(1-naphthoyl)indole.
(2)  An agonist is a chemical substance that binds to a specific receptor of a cell and triggers an activity by the cell. 
An agonist often mimics the action of endogenous or naturally occurring substances.
(3)  The work on Spice was commissioned by the Ministry of Health, Family and Youth. AGES PharmMed is the 
branch of the Austrian Agency for Health and Food Safety responsible for pharmaceuticals. 
(4)  The work on Spice was commissioned by the city of Frankfurt am Main. THC-Pharm is a pharmaceutical company 
that specialises in production of medicinal products based on natural cannabinoids. 
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Subsequently, on 20 January 2009, the German NFP informed the EMCDDA that a team of 
German forensic experts from the University of Freiburg and the German Federal Criminal Police 
Office (BKA) had also identified in ‘Spice’ products the C8 homologue of the synthetic cannabinoid 
CP 47,497 (2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol) (Weissman et al., 1982; 
Compton et al., 1992; Compton et al., 1993; Huffman et al., 2008) — a synthetic cannabinoid 
receptor (CB) agonist with potency greater than THC as measured by the affinity constant Ki (5). 
According to the original publication (Auwärter et al., 2009), not only the C8 homologue, but CP 
47,497 and the non-active trans diastereomers of both compounds, as well as oleamide (6) 
(Lambert and Di Marzo, 1999; Leggett et al., 2004) were also identified in the seven ‘Spice’ 
products tested. CP 47,497 compounds have also been reported by the United Kingdom, Slovakia 
and Finland.
Outside of Europe, in March 2009, the United States Drug Enforcement Administration (DEA, 
2009) reported that another potent synthetic cannabinoid, HU-210 — (6aR,10aR)-9-
(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (7) 
(Mechoulam et al., 1988; Glass and Northup, 1999; Ottani and Giuliani, 2001; Jiang et al., 2005; 
Pertwee, 2005) — had been found in ‘small but verifiable amounts’ in ‘Spice’ products seized by 
the US Customs and Border Protection Service. In June 2009, HU-210 was identified for the first 
time in three ‘Spice’ products in the United Kingdom.
In the first trimester of 2009, two Member States — Denmark and the Netherlands —informed the 
EMCDDA about seizures of another synthetic cannabinoid from the JWH family — JWH-073 (8), a 
lower alkyl homologue of JWH-018. Similarly to JWH-018, this compound acts as a (partial) 
agonist at CB1 and CB2 receptors and, therefore, can be expected to produce cannabis-like effects. 
In both cases, JWH-073 was not detected in ‘Spice’ samples, but as powders seized by law 
enforcement authorities. On 20 April 2009, the German NFP informed the EMCDDA that the 
substance had also been identified in ‘Spice’-like products (Scope and others) in Germany, and it 
has also been identified in Finland.
In October 2009, two new JWH synthetic cannabinoids were reported for the first time by the 
United Kingdom and Germany. The napthoylindole JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)
indole) was found in three separate ‘herbal incense’ products purchased by TICTAC 
Communications Ltd from online shops from February to June 2009. JWH-398 acts as an agonist 
both at the CB1 and the CB2 receptors, having a slight selectivity for the former. The 
phenylacetylindole JWH-250 (2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone) was seized in 
May 2009 by the German Federal Criminal Police; it acts as an agonist mainly at the CB1 receptor.
These relatively obscure substances added to the herbal mixtures sold as ‘Spice’ were all originally 
developed through research aimed at deciphering the molecular and biochemical intricacies of the 
(5)  The affinity constant ([Ki]=nM) is the equilibrium dissociation constant used in drug-receptor binding to describe 
how tightly a ligand (drug) binds to a particular receptor; small variations in Ki values occur between different 
publications. 
(6)  Oleamide is a fatty acid amide which occurs naturally in animals, but which is also synthetically produced for 
industrial use.
(7) HU-210 is a full agonist at CB1.
(8) The IUPAC systematic name of JWH-073 is Naphthalene-1-yl-(1-butylindol-3-yl)methanone.
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endocannabinoid system. None of the above synthetic cannabinoids is internationally controlled as 
a drug and there is no information on any of them having been authorised as a medicinal product 
in the European Union. Importantly, there are no officially published safety data and almost nothing 
is known about their effects in humans. Some of the characteristics of these compounds, e.g. 
volatility (and hence ‘smokability’) and activity in small doses, are likely to present further analytical 
and toxicological challenges.
It can be assumed that different amounts or combinations of synthetic cannabinoids may have been 
added to some ‘Spice’ products to produce cannabis-like subjective effects. Media information 
suggests that some ‘Spice’ products may have been produced in Asia (e.g. China), but it remains 
unclear where and how the actual production of the herbal mixtures, the synthetic cannabinoids 
and their addition to the herbal mixtures takes place.
Although available in some specialised shops, ‘Spice’ products appear to be largely an Internet 
phenomenon. An EMCDDA survey established that ‘Spice’ products are available on national 
websites in two-thirds of the European Union Member States, but the actual accessibility and levels 
of use are difficult to assess. Anecdotal reports of the subjective effects of ‘Spice’ consumption can 
be found in Internet forums and elsewhere and range from reports of a strong cannabis-like effect, 
to the mixture having insignificant or non-detectable psychoactive action.
Responding to potential health concerns, Austria, Germany, France, Luxembourg, Poland, Lithuania, 
Sweden and Estonia (in chronological order) have taken legal actions to ban or otherwise control 
‘Spice’ products and related compounds. Other Member States are also now considering if 
measures in this area are merited.
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1. Introduction and background
The EMCDDA has been monitoring ‘Spice’ products since 2008. The information exchange 
mechanism of the Council Decision (the EWS) (Council Decision, 2005) has facilitated the sharing 
and disseminating of information between the Member States, initially assisting the efforts to 
identify the potential psychoactive components of the herbal ingredients of ‘Spice’. This resulted in 
the dissemination of analytical information (9) useful for identification purposes to the EWS partners 
(Reitox NFPs, Europol, the European Medicines Agency and the Commission). This information was 
obtained from Austria (Austrian Ministry of Health, Family and Youth and the NFP), as well as the 
German NFP and the United Kingdom NFP (10) and the EMCDDA would like to acknowledge the 
important work conducted in this area by these partners.
At the beginning of 2009, a meeting took place between the EMCDDA and Europol to examine the 
information available on ‘Spice’ and related compounds and to decide upon the necessity of 
further actions. The two agencies concluded that, at that time, JWH-018, CP 47,497 and its 
homologues did not fulfil the criteria set up by the ‘EWS Operating guidelines’ (EMCDDA, 2007) to 
trigger the launch of a Europol–EMCDDA Joint report. However, this situation remains under review 
with ongoing monitoring to ensure that, should the criteria be met, appropriate actions could be 
quickly instigated.
It is important to note that the information exchange mechanism of the Council Decision is designed 
and geared towards notification and monitoring of individual substances, which is technically a 
sound practice. Therefore, groups of substances (‘analogues’) cannot be notified, monitored and 
risk assessed as a single category. This would imply that information collection and monitoring, 
potentially leading to risk assessment(s), should be done separately for each individual substance if 
the risk assessment process linked to the Council Decision were to be triggered.
Upon a request from the EMCDDA Management Board (December 2008), and in response to the 
substantial interest of policymakers, experts and the media, in January 2009 the EMCDDA 
launched a survey among the Reitox NFPs to collect some preliminary data on the availability of 
‘Spice’ products in Europe. The first results of the study were presented to an expert meeting 
convened by the EMCDDA in March 2009. The meeting was attended by experts from the Member 
States with particular experience in this area, as well as representatives from the European 
Medicines Agency, EMCDDA staff and the chairperson of the Scientific Committee (11). The 
resulting report includes data and information presented at the meeting; however, interpretations 
and conclusions are those of the EMCDDA. This Thematic paper reflects the situation as of the first 
trimester of 2009 and is intended to provide insight and, as far as it is possible, evidence-based 
answers to the following questions:
1. What do we know about the nature, availability and use of ‘Spice’ products?
2. What do we know about synthetic cannabinoids found in ‘Spice’ products?
(9) MS spectra and chemical information for JWH-018, CP 47,497-C8, HU-210 and JWH-398.
(10) Information from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA).
(11)  See the ‘Acknowledgements‘ section for the list of participants of the EMCDDA expert meeting ‘Spice and related 
synthetic cannabinoids’, 6 March 2009, EMCDDA, Lisbon.
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3. Why did it take such a long time to establish the psychoactive principles in the ‘Spice’ products?
4. Are those products dangerous for the consumer?
5.  Is there a specific demand and will the market of non-scheduled synthetic (designer) 
cannabinoids with a THC-like mode of action (e.g. acting as CB1 receptors) continue to develop?
6.  Where are the synthetic cannabinoids produced, and how are they added to the herbal 
products?
emcdda.europa.eu
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2. Herbal components of ‘Spice’ products
The labels on the colourful ‘Spice’ packages indicate that the product contains between 0.4–3.0 g 
of a mixture said to consist of several potentially psychoactive plants (see Table 1).
Table 1. Herbal components of ‘Spice’ (a non-exhaustive list)
Common name Species Family
Beach bean Canavalia maritima; syn. C. rosea Fabaceae
White and blue water lily Nymphaea alba and N. caerulea Nymphaeaceae
Dwarf skullcap Scutellaria nana Lamiacae
Indian warrior Pedicularis densiflora Orobanchaceae
Lion’s ear/tail, Wild dagga Leonotis leonuru Lamiacae
‘Maconha brava’ Zornia latifolia or Z. diphylla Fabaceae
Blue/Sacred lotus Nelumbo nucifera Nelumbonaceae
Honeyweed/Siberian motherwort Leonurus sibiricus Lamiaceae
Marshmallow Althaea officinalis Malvaceae
Dog rose/Rosehip Rosa canina Roseceae
These plants seem to have been chosen because some of them have been traditionally known as 
‘marijuana substitutes’ so users can expect effects similar to that of smoked cannabis. An 
assumption, based on the known chemical content of the plants, is that at least two of the 
mentioned ingredients, ‘Indian warrior’ (Pedicularis densiflora) and ‘Lion’s tail’ (Leonotis leonurus), 
may have some psychoactive effect. However, there is a lack of information about their complete 
chemical make-up and, overall, little is known about the pharmacology and toxicology of the plant 
materials purportedly contained in the ‘Spice’ products. Thus, no strong conclusions can be drawn 
about the public health implications of the consumption of these mixtures. However, concerns have 
been raised that some of these mixtures may contain heavy metal residues that may be harmful to 
health. Without further analysis, the veracity of this concern is difficult to assess, but in general, the 
smoking of any mixture is likely to be a concern from a public health perspective.
Specific worries about the pharmacology and toxicology of these herbs have to be evaluated in the 
context in which it appears that most of the ingredients listed on the packaging are actually not 
present in the ‘Spice’ products. It is now generally assumed that the biological and psychological 
effects described by users are due to the added synthetic cannabinoids, which are not reported on 
the label. This raises the possibility that there may be a deliberate marketing strategy to represent 
this product as natural. It also raises questions of consumer protection and product 
misrepresentation.
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3.  Synthetic cannabinoid receptor agonists: a brief 
chemical overview
Synthetic cannabinoid receptor agonists, often referred to as ‘synthetic cannabinoids’, are a large 
family of chemically unrelated structures functionally similar to Δ 9-tetrahydrocannabinol (THC), the 
active principle of cannabis. Like THC, they bind to the same cannabinoid receptors in the brain 
and other organs as the endogenous ligand anandamide (12). They were developed over the past 
40 years as potential pharmaceutical agents, often intended for pain management. However, it 
proved difficult to separate the desired properties from unwanted psychoactive effects — see the 
EMCDDA drug profile on synthetic cannabinoids (EMCDDA, n.d.) for a comprehensive review.
The two main cannabinoid receptors (CB) were discovered in the 1980s. Type CB1, found mostly in 
the central nervous system (CNS), is associated with psychoactive effects, while type CB2 is 
associated with the immune system. Other receptors are believed to exist in the CNS and other 
tissues. Anandamide, discovered in 1992, was the first identified substance of several closely 
related endogenous agonists for these cannabinoid receptors.
Δ 9-tetrahydrocannabinol (THC) is the principal naturally-occurring exogenous agonist for CB1 and 
CB2. Following the isolation of THC in the 1960s, a large series of synthetic exogenous 
cannabinoid receptor agonists were synthesised. They fall into four major groups:
•   Analogues of THC, so-called classical cannabinoids, are based on a dibenzopyran ring. They 
were developed from the 1960s and include HU-210 (‘HU’ stands for Hebrew University) 
(Mechoulam et al., 1988; Glass and Northup, 1999; Ottani and Giuliani, 2001; Jiang, 2005; 
Pertwee, 2005), Nabilone and Dronabinol and many others. Some, like Nabilone and 
Dronabinol, have limited therapeutic use, e.g. in treating nausea following chemotherapy. 
HU-210 is reported to have 100 times the potency of THC, as measured by Ki.
•   In the 1970s, Pfizer developed the cyclohexylphenol (CP) series. Examples include CP 59,540, 
CP 47,497 and their n-alkyl homologues (Weissman et al., 1982; Compton et al., 1992; 
Compton et al., 1993; Huffman et al., 2008). In the scientific literature they are referred to as 
‘non-classical’ cannabinoids.
•   In the 1990s, J.W. Huffman et al. at Clemson University, USA created a large series of 
naphthoylindoles, naphthylmethylindoles, naphthoylpyrroles, naphthylmethylindenes and 
phenylacetylindoles (i.e. benzoylindoles) (known as aminoalkylindoles or JWH compounds — 
after the name of their inventor). Examples of naphthoylindoles include JWH-015, its n-pentyl 
homologue JWH-018 (Chin et al., 1999; Uchiyama et al., 2009), JWH-073 (an alkyl homologue 
of JWH-018) (Aung et al., 2000), and JWH-398. An example of phenylacetylindole is JWH-250, 
identified in ‘Spice’ products in Germany (LKA Bayern and Schleswig-Holstein).
•   Miscellaneous compounds, possibly including fatty acid amides (e.g. oleamide). Although similar 
in structure to anandamide, the status of oleamide as a cannabinoid receptor agonist is 
uncertain; it is used as an anti-slip agent and is a common contaminant from plastics.
(12)  Also known as N-arachidonoylethanolamine, anandamide is one of the endogenous ligands for cannabinoid 
receptors in the CNS and other organs.
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Examples from all four groups have been reported in ‘Spice’ and ‘Spice’-like samples in Europe — 
HU-210; CP 47,497 and its homologues; JWH-018, JWH-073, JWH-398, JWH-250; and oleamide. 
(See Annex 1 for the basic chemical features and structure of exogenous synthetic cannabinoid 
receptor agonists found in ‘Spice’ products.)
The above CB1/CB2 agonists are lipid-soluble, non-polar, small molecules (typically 20–26 carbon 
atoms). They are fairly volatile (and hence, ‘smokable’). Many are much more potent than THC, thus 
the ‘typical’ doses may be less than 1 mg. Their detailed pharmacology has not been investigated.
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4.  Forensic identification, pharmacology and 
toxicology of synthetic cannabinoids
Towards the end of 2008, extensive forensic science investigations were undertaken in Germany 
and Austria. In December 2008, chemical analysis revealed that the psychoactive effects of the 
herbal mixture were due to added synthetic cannabinoids. Since then, several analytical laboratories 
in Europe (Germany, Austria, Finland, France, Hungary, Poland, Slovakia, Slovenia and the United 
Kingdom) have confirmed the presence of at least one such substance in ‘Spice’ products.
On 16 December 2008, through a self-report study and chemical analysis of plant extracts and 
plasma samples after consumption, a team of German scientists (Auwärter et al., 2009) clearly 
identified the presence of added synthetic compounds. Using an extract of Spice Diamond, by 
combining the mass spectral information and the results of nuclear magnetic resonance 
spectroscopy (NMR), the authors found the C8 homologue of the synthetic cannabinoid CP 47,497 
to be the main active component of the ‘Spice’ variants analysed.
One day earlier, THC-Pharm, a pharmaceutical company mandated by the city of Frankfurt, had 
found a ‘cannabimimetic’ aminoalkylindole called JWH-018 to be present in some samples of 
‘Spice’ products by comparing one of the unknown mass spectra generated from the extract with 
the mass spectrum of a JWH-018 standard, which they had in stock (Steup, 2008).
Both JWH-018 and CP 47,497-C8 act as agonists at CB1 receptor and, therefore, produce 
cannabis-like effects. Due to their high pharmacological potency in vitro, it is likely that relatively 
low doses are sufficient for activity. The duration of effects in humans compared to THC seems to 
be shorter for JWH-018 (1–2 hours) and considerably longer for CP 47,497-C8 (5–6 hours), as 
reported in a self-experiment (Auwärter et al., 2009). Furthermore, JWH-073 (an alkyl homologue 
of JWH-018) was identified in Scope and other products in Germany, as well as in seizures of the 
substance in Denmark, the Netherlands and Finland.
In June 2009, HU-210 was identified for the first time in Europe, in the United Kingdom. Recently, 
two new synthetic cannabinoids, the napthoylindole JWH-398 and the phenylacetylindole JWH-
250, have been identified in ‘Spice’ products in the United Kingdom and Germany, respectively.
Why did it take such a long time to establish the psychoactive 
principles in ‘Spice’?
A number of factors may have contributed to this problem, among them the content (design) of the 
‘Spice’ products: 
•  listing various herbs on the label that in theory may have cannabis-like effects by themselves; 
•  the extracts of the mixtures rendered very complex matrices; 
•   the addition of high amounts of non-psychoactive compounds such as vitamin E (tocopherol) to 
‘mask’ the active components; 
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•   selection of cannabinoids that are not present in common mass or UV spectra libraries and do 
not show cross-reactivity to commonly used drug test assays based on antibodies.
For these reasons, the synthetic additives are difficult to detect and identify.
More general factors may also have contributed. For example, the legal sale of ‘Spice’ products as 
a commodity via the Internet or in specialised shops, rather than clandestine production and illegal 
circulation as a drug, did not generate seizures or indicate criminality that might have prompted the 
interest and involvement of specialised law enforcement agencies. To some extent, this is a 
conceptual problem reflecting the lack of consensus on how this type of product should be viewed. 
Thus, the distribution and sale of these products took place in a ‘grey zone’ where the potentially 
responsible institutions (public health authorities, consumer protection agencies or the competent 
authorities for medicinal products) did not assume direct responsibility.
Are those products dangerous for the consumer?
The pharmacology of cannabis and THC, the main psychoactive ingredient of the plant, as well as 
the human body’s endocannabinoid system has been known for 15–20 years. Several in vitro and 
animal studies (Aung et al., 2000), including structure-activity relationship studies (Wiley et al., 
1998; Huffman, 2009; Compton et al., 1993; Huffman et al., 2005; Vann et al., 2009) aiming 
mostly at separating the undesired psychoactive effects from the therapeutically useful ones, have 
been published in the medical literature in the last two decades. However, no pharmaceutical 
product has emerged and no human studies with these cannabinoids have been carried out.
So far, little is known about metabolism and toxicology of the synthetic cannabinoid compounds. It 
cannot be assumed that the risks associated with the use of synthetic cannabinoids will be 
necessarily comparable to those seen with THC, and indeed there are some reasons for concerns 
that these drugs may have a greater potential to cause harm. Because the synthetic cannabinoids 
in the ‘Spice’ products have only been tested in the laboratory (in vitro or in animals), the health 
risk of the inhaled smoke is unknown. In the case of JWH-018, it can be speculated that, due to 
structural features, there may be a certain carcinogenic potential. Furthermore, accidental 
overdosing with a risk of severe psychiatric complications may be more likely to occur because the 
type and amount of cannabinoid may vary considerably from batch to batch even within the same 
product. In general, there may be a risk of the appearance of a full CB receptor agonist leading to 
life-threatening conditions if overdosed (unlike THC, which acts only as a partial agonist). 
Furthermore, it seems that tolerance to these synthetic cannabinoids may develop fairly fast, and 
arguably this might be associated with relatively high potential to cause dependence (Zimmermann 
et al., 2009). What is clear is that further studies are needed to assess these risks reliably.
Methods for the forensic analysis of blood samples for synthetic cannabinoids known to be used in 
‘herbal smokes’ are already available in some laboratories (detection of recent intake). However, 
the detection of metabolites in urine samples, which would potentially provide a longer 
observational window, still requires further development. 
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5. EMCDDA survey
Rationale
The considerable professional and public interest in ‘Spice’ products resulted in a number of 
information requests to the EMCDDA: prompted by the lack of information, the Centre launched a 
short survey in January 2009 to collect some basic information on the availability of these products 
in the European Union Member States. The survey was carried out as part of the ongoing work to 
monitor the European drug problem and was a limited exercise that should not be confused with 
the more formal and legally binding data collection procedures possible under the auspices of the 
information exchange mechanism established by Council Decision 2005/387/JHA (Council 
Decision, 2005).
Methodology
A short questionnaire (eight questions, see below) was sent by e-mail to the Heads of Reitox NFPs 
on 20 January 2009. The questions covered ‘Spice’ products and JWH-018, but not CP 47,497 
and its homologues, JWH-073 or HU-210, as at that time these compounds were not yet reported 
to the EMCDDA. However, later the EMCDDA contacted the NFPs and requested them to also 
include information on CP compounds. Responses from all surveyed NFPs (30 out of 30 — 27 EU 
Member States plus Croatia, Turkey and Norway) were received between 23 January and 3 
March 2009. Where necessary, reminders were sent in order to ensure a full coverage of the 
survey, and brief telephone interviews were carried out with clarification questions. The 
questionnaires were completed by a national EWS system correspondent, a national forensic 
expert or the head of the respective focal point, based on their knowledge of the current situation. 
As such, the results should be regarded as an expert opinion.
Results
Availability of ‘Spice’ products
‘Spice’ products were identified in 21 out of the 30 participating countries. For the purpose of the 
survey, ‘identification’ means that these types of products were available in some way in the 
country (confirmation by forensic analysis was not a prerequisite, see the next question below). At 
the time of the survey, ‘Spice’ products were not identified in Belgium, Bulgaria, Denmark, Estonia, 
Greece, Malta, the Netherlands, Norway and Turkey.
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‘Spice’ products and/or JWH-018 identified by means of toxicological or forensic 
analysis
JWH or CP compounds were identified by forensic/toxicological analysis in eight out of 21 
countries where the products were available — Austria, Germany, Finland, France, Hungary, 
Poland, Slovenia and the United Kingdom. In four countries — Cyprus, Luxembourg, Lithuania and 
Sweden — analysis was under way. The following substances were identified:
•   Austria: JWH-018 and CP 47,497-C8 homologue were identified in different ‘Spice’ samples 
(December 2008).
•   Germany: JWH-018, CP 47,497-C8 homologue, but also the leading substance of the CP 47,497 
series were identified in different ‘Spice’ samples (December 2008). Furthermore, JWH-073 was 
found by different laboratories (BKA, Bavarian Police, University of Freiburg, University of 
Braunschweig) in several samples of Scope Vanilla, Scope Wildberry, Scope Sex on the beach, 
Suncoast Herbal Teas SH, Sencation and Forest Humus (information as of 20 April 2009).
•   France: four different ‘Spice’ products (Gold, Diamond, Arctic Synergy and Tropical Energy) 
were ordered directly from the Internet. All contained CP 47,497. Spice Arctic Synergy and Spice 
Tropical Energy were found also to contain JWH-018, vitamin E, caffeine and menthol (February 
2009).
•   Hungary: Spice Diamond and Spice Gold were analysed. The latter was found to contain 
JWH-018; the samples had a high content of chromium (February 2009).
•   Poland: JWH-018 was found in the investigated products Spice Arctic Synergy, Smoke and 
Genie (end of January 2009).
•   Slovenia: in a seizure of a cigarette with the original inscription Spice Gold, CP 47,497-C8 
homologue and vitamin E were found (February 2009).
•   United Kingdom: the MHRA obtained samples of Spice Gold, Spice Silver and Spice Diamond in 
November 2008 from a shop in Bournemouth. Later, they were found to contain JWH-018 (13).
•   Finland: identification (not specified) in products ordered on the web or seized from incoming 
mail.
These data should be interpreted with caution and in the context of the analytical difficulties posed 
by the task of identifying synthetic cannabinoids. Forensic data are limited, in part because these 
substances are not controlled in most Member States and, therefore, unlikely to be submitted to 
forensic science services for analysis. Moreover, when analysis is conducted as a number of JWH 
and CP compounds exist, it is possible that laboratories will not always look for the full spectrum of 
substances and this may result in inconsistencies between reports.
Websites in national languages and other sources of supply
Countries were asked to provide information on national websites offering ‘Spice’ products but also 
to indicate any other sources of supply. In most cases it was reported that ‘Spice’ products were 
(13)  In Jersey, the British Crown Dependency, JWH-018 and CP 47,497 were identified in Spice (data reported to the 
EMCDDA by the United Kingdom NFP on March 2009).
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sold on the Internet (see Annex 2) and less frequently in head shops and in smart shops (Austria, 
Germany, Hungary, Ireland, Luxembourg, Lithuania, Latvia, Portugal and the United Kingdom), sex 
shops (Lithuania), and fuel stations (Luxembourg).
Patterns of use (user groups, settings)
Information on patterns of use was collected mostly through Internet forums, where users are 
sharing experiences. ‘Spice’ products can be smoked, sometimes together with cannabis, or 
consumed orally as an infusion. Spain reported that ‘users recommend using pipes’ while Slovakia 
reports that ‘the fumes of the burning mixture could be inhaled’.
It was reported that ‘Spice’ products were generally used by teenagers and young people. Other 
notable issues reported by the countries are:
•   cannabis users have used ‘Spice’ products as a substitute, to enable them to pass drug-screening 
tests (Germany);
•  people interested in using legal biogenic (14) drugs are using ‘Spice’ (Germany);
•   sensation-seekers and experimental drug users are attracted to ‘Spice’ by media coverage 
(Germany);
•  ‘Spice’ has been reported as a problem in prisons and the probation service (Sweden).
Information on dosage, effects and reported health problems
Information reported in this area is very limited, which can be explained by the fact that ‘Spice’ 
products have arrived relatively recently on the drug market.
An article published by a German researcher (Auwärter et al., 2009) reports that the effects of 
‘Spice’ are similar to the effects of cannabis consumption.
To prove pharmacological activity and to gain drug positive blood and 
urine samples, a self-experiment was conducted by two of the authors. 
One cigarette containing 0.3 g of Spice Diamond was smoked and 
several blood and urine samples were collected. Approximately 10 
minutes post application, the first noticeable effects occurred in the form 
of considerably reddened conjunctivae, significant increase of pulse 
rates, xerostomia (dry mouth) and an alteration of mood and 
perception. In objective psychomotor tests, no abnormalities were 
detected, although the subjects had the impression of being moderately 
impaired. The effects continued for about six hours under slow 
attenuation. The whole next day, some minor after-effects were still 
noticeable. These findings were consistent with the majority of reports 
(14) Produced by living organisms or biological processes; naturally occurring.
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available on the Internet and confirmed the presence of 
pharmacologically active compounds (15).
(Auwärter et al., 2009, p. 832)
Some emergency cases were reported in Germany (‘effects on the cardiovascular and nervous 
system like tachycardia and, in some cases, short-term loss of consciousness’). These had been 
reported in the mass media and via personal communication (Poison Control Centre, Mainz). Italy 
reported a single case of a 53-year old woman with diabetes, who smoked ‘Spice’ and was 
treated in an emergency room, one hour after consumption. She was in an excited state and in 
psychomotor agitation that was successfully treated with benzodiazepines. For a few hours, the 
patient was monitored and no alteration of vital parameters was registered. After 12 hours in an 
emergency room, the patient was discharged in a stable condition. In all cases, the presence of the 
synthetic cannabinoids was not confirmed by toxicological analysis.
During 2008, the Swedish Poison Information Centre had 51 inquiries (45 cases in total) — 40 of 
these cases originated from the health care system, i.e. physicians treating patients who reported 
use of ‘Spice’. None of these cases was toxicologically confirmed.
Based on a few accounts from counselling centres in Austria, the subjective effects of ‘Spice’ were 
reported as highly variable, ranging from mild to strong, and it was reported that they could be 
similar to cannabis or, alternatively, completely different. Similar reports from users in Romania 
suggested that ‘Spice’ tasted like herbal cannabis and the effects could be similar or even ‘better’.
Specific measures to address availability and/or use of ‘Spice’ products
In Austria, Cyprus, Finland, Germany, France, Hungary, Italy, Lithuania, Luxembourg, Poland (‘legal 
highs’ in general), Sweden, Slovenia and the United Kingdom, the availability and use of ‘Spice’ 
products were reported to be of concern. Measures have been taken in some Member States in 
order to limit the availability, constrain use and avoid any potential health risks for those using the 
product. Eight countries (Austria, Germany, France, Luxembourg, Poland, Lithuania, Sweden and 
Estonia) have enacted specific legal measures (see section 7, page 19). In Hungary, Portugal, 
Slovakia and the United Kingdom, regulations are under consideration or in process or in 
preparation.
Additional information on ‘Spice’ products and/or JWH-018 reported by national 
informants
Experts completing the questionnaire were also asked to report any additional elements or 
observations that they consider useful. These are noted below.
•  Austria noted that CP 47,497 and HU-210 seemed more important than JWH-018.
(15)  C8 homologue of CP 47,497 was found to be the main active component of the investigated ‘Spice’ variants (see 
section 4, page 11). 
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•   Germany noted that it remained unclear how synthetic cannabinoids were added, and which 
was the source of the synthetic cannabinoids.
•   Italy noted that JWH-018 was being researched as an analgesic to be used in transdermal 
patches, and that the Japan Shohin-Bonsai Association and the International Bonsai Society had 
certified JWH-018 as a safe fertiliser for use at bonsai plant international competitions.
•   France reported that information from the French EWS suggested that the presumed target 
population for these drugs (mainly partygoers) showed little interest in these types of products.
•   Hungary noted that an Internet site marketed ‘Spice’ products as coming from an eco-farm, 
without any chemical substances present.
•   The Netherlands noted that websites selling ‘Spice’ products, even though they had a .nl domain, 
excluded the Netherlands from delivery, and consequently no consumption of ‘Spice’ products 
was reported in the country.
•   The United Kingdom noted that a Google search produced over 11 million hits for Spice Gold 
(higher than most of the commonly used illicit drugs).
Similar products being marketed in Member States
Similar herbal products with different brand names were mentioned by Germany, Lithuania, Poland 
and the United Kingdom (see Annex 2). In most cases, advertising strategies for these products 
suggested they would create effects similar to ‘Spice’ products.
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6. Internet information
EMCDDA Internet annual snapshot
To identify current developments in the online drug market, the EMCDDA initiated in 2008 an 
annual snapshot study. The snapshot was repeated in 2009 and surveyed 115 online shops based 
in 17 European countries. EU country code domains (e.g. United Kingdom, France, Germany) or 
other indications of being EU-based (e.g. contact address) were used to identify the country of 
origin. In 2009, the majority of online retailers identified were based in the United Kingdom (37 %), 
Germany (15 %), the Netherlands (14 %) and in Romania (7 %).
Among 115 investigated online shops, 48 % of the retailers based in 14 different European 
countries offered ‘Spice’ products for sale. For the majority of these, retailers were based in the 
United Kingdom (53 %), followed by Romania, Ireland and Latvia. ‘Spice’ products were no longer 
offered for sale in online shops based in Germany, Austria and France following legal actions to 
ban or otherwise control ‘Spice’ products.
The average Internet price of ‘Spice’ products varied, but was generally between EUR 20 and 
EUR 30 per 3 g package, depending on the country and the ‘strength’ of the product. Provided that 
one 3 g package is sufficient for seven ‘joints’ (0.4 g per joint), the price is roughly comparable to 
that of cannabis in Europe, i.e. approximately EUR 3–4 per joint.
Compared to 2008, a greater range of alternative smoking blends to ‘Spice’ was being advertised 
by retailers. A total of 27 different herbal smoking blends were identified across all investigated 
retailers (e.g. Yucatan Fire, Sence, Genie). They were advertised as containing plant-based 
ingredients, however, according to retailer-supplied information, some also contain the 
hallucinogenic mushroom Amanita muscaria (e.g. Pep Spice Twisted).
Among the alternatives offered for sale in Austria and Germany were herbal smoking blends such 
as Space, Scope, Relax and Bull Titan, sold as room odourisers (incense).
The EU Psychonaut web-mapping project
Since 2007, the EU Psychonaut web-mapping project (16) has recorded a rapid diffusion of ‘Spice’ 
products over the Internet. More specifically, Google Insights shows that a substantial amount of 
searches were conducted on ‘Spice’ products from the end of 2004. However, these increased 
exponentially in the second part of 2008, presumably as media reports of the drug raised 
awareness. The majority of the searches for Spice Gold, for instance, came from the Russian 
Federation, followed by Austria, Sweden, Hungary, Poland, Germany and the United Kingdom. 
Interestingly, these searches were also linked with key words such as: ‘spice gold shop’, ‘spice gold 
buy’ and ‘spice gold smoke’.
(16)  The Commission-funded Psychonaut web-mapping project continuously monitors the web for novel compounds, 
using nine languages, with the support of different tools/software (e.g. Google Insights, Blue Crab, Boolean 
Search, InSite, Advanced Web Ranking and SerpSpy). The project monitors regularly more than 200 websites, 
forums and blogs that provide information on many compounds. 
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7.  Control measures
Neither the purported herbal ingredients of ‘Spice’ and ‘Spice’-like products, nor any of the 
synthetic cannabinoids found in them are internationally controlled under the 1961 or 1971 UN 
drug control conventions (Single Convention on Narcotic Drugs, 1961; Convention on Psychotropic 
Substances, 1971). The individual herbal ingredients of ‘Spice’ products do not seem to be 
controlled under drugs control legislation (i.e. national legislation implementing the 1961 and 1971 
UN conventions) in any of the European Union Member States, except in Poland (see below). 
Responding to potential health concerns, Austria, Germany, France, Luxembourg, Poland, Lithuania, 
Sweden and Estonia have recently taken legal actions to ban or otherwise control ‘Spice’ products 
and related compounds.
In Austria, a decree under the Pharmaceutical Law (Federal Gazette II No 6/2009 of 7 January 
2009) declares that ‘smoking mixes containing JWH-018’ are prohibited from being imported or 
marketed in the country. The identification of CP 47,497, its homologues CP 47,497-C6-homologue, 
CP 47,497-C8-homologue, CP 47,497-C9-homologue and HU-210 led to further amendment of the 
Pharmaceutical Law, and the Decree published in the Federal Gazette II No 6/2009 of 3 March 
2009 prohibits the sale and import of products containing these substances. The Austrian 
authorities continue to monitor and review the situation in order to decide whether control is 
required under its Narcotic Drugs Law.
In Germany, following a rapid control under the Pharmaceutical Law, an emergency regulation in 
effect from 22 January 2009 brought three cannabinoids found in ‘Spice’ products and two 
pharmacologically active homologues under Annex II of the Narcotic Drugs Law. These include 
JWH-018, CP 47,497 and its three homologues (for comparison, also listed in this table are THC 
and 1-benzylpiperazine — BZP). Unauthorised sale and marketing, production, acquisition and 
possession of these active agents in any form are therefore illegal. This fast-track regulation is valid 
for one year; during this time, the German government may pass a standard regulation to bring the 
substance permanently under control.
Following a scheduling proposal by the Narcotics and Psychotropics National Commission (CNSP) 
of 19 February 2009, on 24 February the French Minister of Health and Sports classified six 
synthetic cannabinoids as narcotics in Annexe IV of the Arrêté of 22 February 1990. These are 
JWH-018, CP 47,497 and its three homologues that were found in ‘Spice’ products in France as 
well as HU-210.
By a decree on Amendment of Regulation on Psychotropics signed on 20 April 2009, Luxembourg 
added as of 4 May 2009, CP 47,497, JWH-018 and HU-210 and other ‘synthetic agonists of 
cannabinoid receptors or synthetic cannabinomimetics’ to the list of psychotropic substances subject 
to the national drug control legislation.
The Polish Parliament adopted the Act of law amending the Act on Counteracting Drug Addiction 
on 20 March 2009 (Dz.UNr 63 z 23 kwietnia 2009/pozycja Nr 520), which entered into force on 
8 May 2009. According to this act, JWH-018 and some of the claimed herbal ingredients of 
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‘Spice’, such as Leonotis leonurus and Nymphaea caerulea, were put on the list of controlled 
substances.
In Lithuania, JWH-018, JWH-073, HU-210, CP-47,497 and homologues were added to the first 
schedule of plants, narcotic and psychotropic substances, by a decree of the Health Ministry that 
entered into force as of 27 May 2009.
The Swedish government classified seven synthetic cannabinoids (CP 47,497, and its C6, C8, and 
C9 homologues, JWH-018, JWH-073 and HU-210) as narcotics in the law 1992:1554. The 
Government decision was made on 30 July 2009 and this entered into force on 15 September 
2009.
In Estonia, from 24 July 2009, the following synthetic cannabinoids are controlled by the Narcotic 
Drugs and Psychotropic Substances Act: CP 47,497, and its C6, C8, and C9 homologues, HU-210 
and JWH-018.
On 12 August 2009 the Advisory Council on the Misuse of Drugs (ACMD) advised the United 
Kingdom government to classify and control a broad range of synthetic cannabinoids by the 
Misuse of Drugs Act (1971) (Advisory Council on the Misuse of Drugs, 2009). The recommendation 
proposed the cannabinoids to be brought under control by means of generic definitions, in order to 
cover the products that are, or could in the future, be used in preparations. Five substances were 
named for specific control: HU-210, WIN-55, 212-2, HU-243 and CP 50,5561. These five and the 
generically defined substances should be placed under Schedule 1, while Nabilone (a component 
of the existing medicinal product Cesamet®) should be placed under Schedule 2 of the Misuse of 
Drugs Regulations (2001).
In Hungary, a formal decision of 9 March 2009 (OTH 233-10/2009 and KNRI 3991-3/2009) of 
the Regional Chief Medical Officer on behalf of the Central Hungarian Regional Institute of 
National Public Health and Medical Officer’s Service, prohibits the distribution of herbal mixtures 
named as Spice Gold, Spice Diamond and Sence and any other products containing the same 
herbal mixture. The decision is not an overall prohibition of the distribution of ‘Spice’ products, but 
solely applies to a specific distributor. Furthermore, Hungary reported that it is working on the 
suppression of distribution of ‘Spice’ ingredients that are listed as plants not allowed for food 
supplements. Two ingredients of ‘Spice’ (Nelumbo nucifera and Nymphaea alba) are already listed 
in an annex of a regulation controlling plants and parts of plants not recommended for use as food 
supplements.
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8. Conclusions
The appearance of various ‘herbal highs’ — herbal mixtures whose contents may vary from 
innocuous, non-psychoactive vegetable matter to synthetic chemicals with marked psychoactive 
properties poses a range of difficult questions for drug policy. These range from the conceptual — 
how to define which products are of interest, given that the wide variety of ‘Spice’ and ‘Spice’-like 
products and herbal mixtures are sold for many reasons, including alternative health remedies, and 
as foodstuffs — to the practical and methodological — how to monitor the products sold, identify 
the synthetic compounds that they may contain and assess their health risks.
‘Spice’ and other ‘herbal’ products are often referred to as ‘legal highs’ or ‘herbal highs’, in 
reference to their legal status and purported natural herbal make-up (McLachlan, 2009; Lindigkeit 
et al., 2009; Zimmermann et al., 2009). However, albeit not controlled, it appears that most of the 
ingredients listed on the packaging are actually not present in the ‘Spice’ products and it is seems 
likely that the psychoactive effects reported are most probably due to added synthetic 
cannabinoids, which are not shown on the label. There is no evidence that JWH, CP and/or HU 
compounds are present in all ‘Spice’ products or even batches of the same product. Different 
amounts or combinations of these substances seem to have been used in different ‘Spice’ products 
to produce cannabis-like effects. It is possible that substances from these or other chemical groups 
with a cannabinoid agonist or other pharmacological activity could be added to any herbal 
mixture (17) (Griffiths et al., 2009).
The emergence of new, smokable herbal products laced with synthetic cannabinoids can also be 
seen as a significant new development in the field of so-called ‘designer drugs’. With the 
appearance, for the first time, of new synthetic cannabinoids, it can be anticipated that the concept 
of ‘designer drugs’ being almost exclusively linked to the large series of compounds with 
phenethylamine and tryptamine nucleus will change significantly (18). There are more than 100 
known compounds with cannabinoid receptor activity and it can be assumed that further such 
substances from different chemical groups will appear (with direct or indirect stimulation of CB1 
receptors). So far, the ‘Spice’ and ‘Spice’-like preparations in Europe have been found to contain at 
least nine new substances from three chemically distinct groups of synthetic cannabinoids (JWH, CP 
and HU), plus a fatty acid amide with cannabinoid-like activity (oleamide). This presents an 
ongoing challenge, not only for their forensic and toxicological identification, but also for risk 
assessment and the development of possible control strategies.
At present, almost nothing is known about the pharmacology, toxicology and safety profile of such 
compounds in humans. However, since the type and amount of added synthetic cannabinoids may 
(17)  For example, in February 2009, the Austrian Federal Ministry of Health analysed a sample of Highdi s´ 
Almdröhner leading to identification of mitragynin (the main psychoactive alkaloid of the plant Kratom). Similarly, 
in June 2009, a metabolite of the synthetic opioid analgesic Tramadol was found by German researchers in an 
incense preparation called ‘Krypton’, advertised as a Kratom-based product. 
Kratom is controlled in several south-east Asian states, but in the EU only Lithuania, Denmark and Latvia control 
both the plant and its main psychoactive principle. 
(18)  Phenethylamines are also referred to as amphetamine type stimulants — a group that includes amphetamines 
and ecstasy drugs (MDMA and its congeners); the tryptamine group includes drugs like psilocin, DMT and DET.
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vary considerably and some of the compounds may be active in very small doses, the possibility of 
accidental overdosing with a risk of severe psychiatric complications cannot be excluded. 
Furthermore, the appearance of full CB receptor agonists could potentially lead to life-threatening 
conditions in the case of overdose.
Media information suggests that some ‘Spice’ products may have been produced in Asia (e.g. 
China), whereas the synthetic cannabinoids may have been produced in various countries that offer 
cheap organic syntheses. However, it remains unclear where and how the actual production of the 
herbal mixtures, the synthetic cannabinoids and their addition to the herbal mixtures takes place. In 
terms of detecting the availability of new synthetic drugs, the ‘Spice’ phenomenon serves as a 
useful example of how these developments can be difficult to detect. First, because ‘Spice’ was sold 
as a commodity only available through the Internet, or in specialised shops, rather than through 
clandestine production and illegal circulation, this did not generate seizures or indicate criminality 
that might have prompted the interest and involvement of specialised law enforcement agencies. 
Second, the limited knowledge about the chemistry and effects of the new compounds contributed 
to the creation of a ‘grey zone’ where the potentially responsible institutions (public health 
authorities or the competent authorities for medicinal products) did not assume immediate 
responsibility. A question for the future is what sort of mechanisms are appropriate to monitoring 
the appearance of products such as ‘Spice’ and accessing their possible impact? It appears likely 
that if such developments are to be detected at an early stage, a more proactive strategy may be 
necessary.
In many countries where ‘Spice’ and related substances are available, they have now become a 
concern. Various national control measures have been implemented in Austria, Germany, France, 
Luxembourg, Poland, Lithuania, Sweden and Estonia and are under consideration in other Member 
States. Nevertheless, the sheer number of potentially psychoactive synthetic cannabinoids means 
that control measures targeting individual chemicals can easily be circumnavigated. Therefore, it 
may be useful to consider experiences from Member States where a more generic approach to 
controlling drugs exists. Furthermore, even if control legislation is adopted, the unavailability of 
analytical data and reference samples, as well as methodologies for toxicological identification of 
metabolites in urine, are likely to pose challenges to the effective implementation of control 
measures.
The extent to which ‘Spice’ products are used in Europe is unknown, and the users seem to be a 
heterogeneous group. They may include those wanting a legal alternative to illegal drugs, or drug 
users wishing to pass successfully an employment/other drug testing procedure aimed at detecting 
illicit drug use. This may be an important issue for any setting where drug abstinence control is 
obligatory (e.g. specific psychiatry or prison settings, driving liability testing, etc.). In general, it can 
be argued that legally available substances that can be legitimately promoted may have a greater 
potential for diffusion than controlled substances, especially if the price is comparable and they 
deliver similar effects. However, to date as far as we can tell, the substances JWH-018, JWH-073, 
JWH-398, JWH-250, CP 47,497 and its C6, C8 and C9 homologues, and HU-210 have not been 
widely used as psychoactive drugs in their own rights, but have been surreptitiously added to 
‘Spice’ products, which have been misrepresented as herbal products. Therefore, it remains an 
open question if there is, or will be, a wider, specific demand for any of these particular 
substances. With this in mind, the need for further action as stipulated by Council Decision 
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2005/387/JHA (Council Decision, 2005) remains an option for future review. The EWS will remain 
vigilant in this respect, as various new (‘Spice’ or ‘Spice’-like) herbal products with different 
packaging and names appear to be continuously appearing. This, together with the variety and 
number of synthetic cannabinoids (or other substances) that could be potentially added to the 
herbal products, continues to pose challenges for identification, monitoring and risk appraisal of 
the phenomenon.
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Annex 2
List of additional names and national websites collected through the questionnaire 
on ‘Spice’ products
Country Additional names List website
Belgium http://www.cannaclopedia.be/ (not for supply)
Czech Republic http://www.spiceceska.com/
Germany http://www.spice-store.de/ (‘Spice’ is no longer available)
http://smoketown-headshop.de/ (‘Spice’ is no longer available)
http://www.spice-nice.de/ (‘Spice’ is no longer available)
http://www.udopea.de/ (‘Spice’ is no longer available)
http://www.jsy-store.de (‘Spice’ is no longer available)
http://www.smoketime.de (‘Spice’ is no longer available)
http://www.spiceladen.de/ (all products are JWH-018 free)
http://www.hanf-hanf.at (‘Spice’ is no longer available)
Ireland Smoke, Sence and Chill X http://www.nirvanaheadshop.com/
http://www.irishheadstores.com/
Spain 2Spicy, Algerian Blend www.spice-gold.eu/ES/spice_introduction_ES.html
www.sjamaan.com/es/index.html
www.cahuinadencul.com.ar
www.psicoactivo.cl/index.php
www.azarius.es
www.laplantamagica.com
www.grasscity.com/is-bin/INTERSHOP.enfinity/WFS/SJV-Grasscity-
Site
France Yucatan Fire, Mojo, Sence, Genie http://www.biosmoke.com/ 
http://buythemg.com/
Italy http://www.sjamaan.com/it/0155_Spice_Gold_-_3_gr_-_10_
unita.html
http://www.narghile.it/spice_gold.htm
http://www.grasscity.com/is-bin/INTERSHOP.enfinity/WFS/
SJV-Grasscity-Site/it_IT/-/USD/ViewStandardCatalog-
Browse?CatalogCategoryID=3.fAqAHAi6YAAAETFqcdTLpm
http://www.spice-gold.eu/IT/spice_background_IT.html
http://italian.alibaba.com/search/indole-1.html
http://moksha.splinder.com/post/19371311/JWH-
018:+ingrediente+attivo+de
Latvia Sence, Smoke, Yucatan Fire, Genie Incense, 
Majo, Morning Glory (Ipomea). Also possible 
to buy Kratom, Salvia and Poppers
www.bongs.lv
www.spais.lv
www.happyfaces.lv
Lithuania Yukatan Fire, Genie, Spice Gold Joint, Algerian 
Blend, Blue Lotus, Chacruna, Jurema, Ourinhos, 
Marshmallow, Anadenathera Colubrina, 
Damiana, Calea, Wild Dagga, Sincuichi, 
Aphrodisia, Ice Bud, Smoke, Ex-ses Gold, 
Ex-ses Platinum, Cahoots, Chill, Ignite, Red Ball, 
Vortex, Dream, Zohai RX, Spike 99 Ultra, Spike 
99 — herbal mixes for smoking; Snow Blow, 
Charge, Blow Out, Snow Berry — herbal mixes 
for snuff
www.buzas.lt
www.headshop.lt
 www.laimeskrautuve.lt
www.rastashop.lt
www.amsterdamas.eu
spicegold.biz
herbalking.tk.
Hungary Yucatan Fire, Sence www.zolderdo.hu
http://www.greenshop.hu/
Netherlands www.consciousdreams.nl
www.desjamaan.nl
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Country Additional names List website
Poland Smoke: Scullcap extract, Kanna extract, 
Blue Lotus extract, Kratom leaves, Wild 
Dagga extract, Mexican Tarragon extract, 
Red Raspberry Leaf, Dream Herb extract, 
Verbascum Thapsis, Leonurus Sibiricus extract, 
Jasmine Flower…
Sence: Scullcap extract, Kanna extract, 
Blue Lotus extract, Kratom leaves, Wild 
Dagga extract, Mexican Tarragon extract, 
Red Raspberry Leaf, Dream Herb extract, 
Verbascum Thapsis, Leonurus Sibiricus extract, 
Jasmine Flower…
Ex-ses: Baybean (Canavalia martima), Blue 
Lotus (Nymphaea caeulea and Nymphaea 
alba), Indian Warrior (Pedicularis densiflora), 
Maconha Brava (Zornia latifolia), Damiana 
(Turnera aphrodisiaca), Marshmallow (Althaea 
officinalis)…
Dream: Baybean — Canavalia maritima, Blue 
Lotus — Nymphaea caerulea and Nymphaea 
alba, Dwarf scullcap — Scuttelaria nana, 
Indian Warrior — Pedicularis densiflora,  
Lion’s Tail — Leonotis leonurus, Maconha Brava 
— Zornia latifolia, Pink Lotus — Nelumbo 
nucifera, Siberian Motherwort — Leonurus 
sibiricus
www.dopalacze.com
http://www.smartszop.pl/
www.legalfun.pl
www.seed.pl
Romania products labelled as being of ‘herbal origin’ — 
Skunk, Genie, Ice, Spike, etc.
www.spiceblend.ro
www.etnoplant.ro
www.spiceshoponline.ro
www.spicegold.ro
www.spice-gold.ro
espice.ro
www.magic-ro.com
www.ihigh.ro
www.etnotrip.ro
Slovenia www.marlek.si
www.cannajoy.com
www.headshop.si
www.kanabis.org (in croatia)
Slovakia http://www.spice-shop.sk/
http://www.spice-shop.k/spice-incense-online-shop
http://www.spice-shop.sk/spice-zlozenie
http://www.champlegals.co.uk/showthread.php?t=8075&page=2
http://www.cannabisculture.com/v2/node/16909
http://www.tradekey.com/product_view/id/811392.htm
http://www.erowid.org/chemicals/spice_product/ 
Finland Yukatan Fire, Dream, Sence and Smoke
Sweden Mojo, Genie and Zohaii http://www.spicenordic.com/index.php
http://www.prylshoppen.se/index.php
Croatia http://www.kanabis.org
http://vutra.org/ 
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Legal notice
This report is based on the contribution of the Reitox early-warning system and the results of 
the EMCDDA expert meeting ‘Spice and related synthetic cannabinoids’, which took place 
on 6 March 2009 in Lisbon. The original version of the report has been updated on a 
regular basis, following the identification of new substances and implemented control 
measures.
This paper has no legal meaning under the terms of Council Decision 2005/387/JHA.
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protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences 
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